Skip to content
ESMO 2018 logo

ESMO 2018

11 interviews

European Society for Medical Oncology Congress

Interviews and expert commentary from ESMO 2018 — study authors and key opinion leaders discuss the findings and their clinical implications.

Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”

Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”

MUNICH—A “salutary lesson” was reported by researchers investigating therapy for oropharyngeal cancer at the 2018 annual congress of the European Society for Medical Oncology (ESMO). It ca

12 November 2018
Which New Combination for Metastatic Renal Cell Cancer?

Which New Combination for Metastatic Renal Cell Cancer?

MUNICH—A leading European oncologist acknowledged the impressive life-extending potential of new drug combinations for metastatic renal cell carcinoma discussed at the 2018 annual congress of the Euro

12 November 2018
Two Drug Combination Doubled Kidney Cancer Progression Free Survival

Two Drug Combination Doubled Kidney Cancer Progression Free Survival

MUNICH— A doubling of progression free survival (PFS) and objective response rate (ORR) was observed in patients who had their previously untreated advanced renal cell cancer (RCC) treated with a comb

7 November 2018
ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 

ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 

MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK ge

7 November 2018
First Line PARP Inhibition For Ovarian Cancer Assessed

First Line PARP Inhibition For Ovarian Cancer Assessed

MUNICH—The role of poly ADP ribose polymerase (PARP) inhibitors for treating newly diagnosed advanced ovarian cancer was under review at the 2018 annual congress of the European Society for Medical On

2 November 2018
BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib

BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib

BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib MUNICH—An “unprecedented improvement” in progression free survival (PFS) was observed in the randomized controlled

1 November 2018
PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression

PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression

MUNICH— Immunotherapy with the anti programmed death ligand 1 (PD-L1) checkpoint inhibitor atezolizumab in combination with nab-paclitaxel chemotherapy prolonged progression-free survival (PFS) among

31 October 2018
Genomically Targeted Therapy Delays Advanced Breast Cancer Progression

Genomically Targeted Therapy Delays Advanced Breast Cancer Progression

MUNICH—A combination of the phosphoinositide 3-kinase (PI3K) inhibitor alpelisib plus fulvestrant significantly extended progression free survival (PFS) compared to placebo plus fulvestr

31 October 2018
Palbociclib Combination Prolongs Life After Breast Cancer Hormone Therapy

Palbociclib Combination Prolongs Life After Breast Cancer Hormone Therapy

MUNICH—Patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer who were treated with a combination of the cyclin dependent kina

29 October 2018
Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer

Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer

MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSC

27 October 2018
Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib

Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib

BARCELONA—Oral cabozantinib “significantly improved” overall survival (OS) and progression free survival (PFS) compared to placebo in patients with advanced hepatocellular carcinoma(HCC) w

15 October 2018